CCR4 is expressed by regulatory T (Treg) cells, which are responsible for the immune response in GVHD, suggesting that mogamulizumab’s anti-CCR4 activity could exacerbate GVHD by depleting Treg cells [9]. This evidence concerns the gene CCR4 and graft versus host disease.